Investor Presentaiton slide image

Investor Presentaiton

Balanced Approach to Capital Allocation Cash flow from Operations $B $3.7 $3.3 $3.0 $1.9 $4.8 Business Development Q3 2022 Q4 Q1 Q2 Q3 2022 2023 2023 2023 $B Q3 2023 Total Cash* -$8.0B ~$37.6B • Prioritize opportunities to further diversify portfolio & strengthen long-term outlook - Entered into agreement to acquire Mirati Therapeutics; planned close by 1H 2024 Balance Sheet Strength Maintain strong investment-grade credit rating Returning Cash to Shareholders Total Debt Strong operating cash flow generation ll Bristol Myers Squibb Q3 2023 Results *Cash includes cash, cash equivalents and marketable debt securities **Subject to Board approval Note: YTD operating cash may not add due to rounding • Continued annual dividend growth** Opportunistic share repurchase - Executed $4B ASR Agreements in Q3'23 - Approx. $2B remaining share authorization Not for Product Promotional Use 20
View entire presentation